Market research
SCNX Scienture Holdings, Inc.
NASDAQ USD Healthcare
Latest close
As of 02 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 37.5
- Dividend yield
- Not available
- Beta
- 4.08
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
- ISIN
- Not available
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 37.5
- Dividend yield
- Not available
- Beta
- 4.08
About
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Research context
Scienture Holdings, Inc. appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Pharmaceutical Retailers
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the SCNX discussion.
No comments yet
Start a focused discussion about SCNX.